Table 2.
Participant Treatment Arm | Drug | Cmax (ng/mL) | tmax (h) | AUCo-τ (ng*h/mL) | (h) |
---|---|---|---|---|---|
Arm 2, participant 1 | Efavirenz | 4,780 | 2.00 | 42,523 | 26.5 |
Arm 1, participant 2 | Ritonavir | 1,270 | 1.00 | 5,512 | 3.53 |
Arm 1, participant 2 | Saquinavir | 3,570 | 2.00 | 19,640 | 5.98 |
τ, Twenty-four hours for efavirenz and 12 hours for saquinavir/ritonavir.
AUCo-τ = area-under-the-plasma-concentration-time curve over one dosing interval; Cmax = maximum observed plasma concentration; tmax = time to reach the maximum observed plasma concentration; = apparent elimination half-life.